OptiBiotix Health PLC Non-exclusive distribution agreement for SlimBiome (3647C)

TIDMOPTI

RNS Number : 3647C

OptiBiotix Health PLC

01 October 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Non-exclusive distribution agreement for SlimBiome(R)

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a distribution agreement with CTC Holding BV ("CTC Group"). The agreement grants CTC Group a non-exclusive licence to distribute OptiBiotix's SlimBiome(R) weight management technology in the Philippines, Vietnam, Indonesia and Colombia.

CTC Group is an international privately-owned company established in the 1890s with 12 sales offices covering Europe, South and Central America, Caribbean and China, with its headquarters in Amsterdam. They provide innovative and value-added solutions for food, beverages and personal care products, focusing on natural, functional and scientific ingredients.

SlimBiome(R), a patented combination of natural ingredients developed by nutritional experts to provide hunger free weight loss will be promoted as part of their food innovation and solutions platforms. This agreement will extend SlimBiome's(R) commercial reach into the ASEAN and South American markets where functional ingredients and supplements play a vital role in weight management, health and beauty. The Philippines has a growing population with an increase in obesity related health issues as a result of adopting a more western diet. The CTC Group views both SlimBiome (R) and SlimBiome products as being the ideal solution to address this need.

The CTC Group will use its best endeavours to develop and expand the use of SlimBiome (R) through their customer network as well as existing partnerships focused on weight management and healthy living.

Christina Wood, Sales & Marketing Director of OptiBiotix, commented: "We are pleased to announce the signing of this non-exclusive distribution agreement with the CTC Group to incorporate SlimBiome(R) into a range of applications targeting hunger free sustainable weight loss. This extends our commercialisation of SlimBiome(R) into ASEAN markets where we have identified a strong consumer need for both weight loss and weight management products. CTC conducted a trial of SlimBiome in OptiBiotix's GoFigure's products which showed an average weight loss of 3lbs per week. This is consistent with OptiBiotix's own scientific and consumer studies which show these food products help customers to manage their weight loss by reducing food intake without food cravings. As we build the range of applications, products and geographic scope of SlimBiome(R) with new partners, the scale of the opportunity enlarges, allowing us to fully exploit the revenue generating potential of this ground-breaking technology."

For further information, please contact:

 
 OptiBiotix Health plc                                           www.optibiotix.com 
 Stephen O'Hara, Chief Executive                               Contact via Walbrook 
                                                                              below 
 
 Cairn Financial Advisers LLP (NOMAD)                            Tel: [phone] 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                              Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRZMGZLMRDGRZM

(END) Dow Jones Newswires

October 01, 2018 02:00 ET (06:00 GMT)